Gastroesophageal Reflux Disease (GERD)Phase 3NCT00658775
Rabeprazole Extended-Release, 50 mg, Versus Esomeprazole, 40 mg, for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
A Phase 3 study testing Rabeprazole sodium and Esomeprazole in people with Gastroesophageal Reflux Disease (GERD), run by Eisai Inc. at 83 sites in 14 countries.
Trial summary
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD). Read more about this study
- Who is it for?
- Ages 18 to 75 years
- Conditions the study is for
- Gastroesophageal Reflux Disease (GERD)
- What is being tested?
- Rabeprazole sodium and Esomeprazole
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1,069 participants
- Where
- 83 sitesin 14 countries
- Study dates
- Feb 2008to Jan 2010
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 75 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Male or female, ages 18 to 75 years.
- History of GERD symptoms for at least 3 months immediately before screening.
- Heartburn for at least 2 days a week for at least 1 month before screening.
- Esophageal erosions of LA Grades C or D based on EGD taken within 14 days prior to enrollment.
- Subjects who are H. pylori negative based on a screening test.
- Females should be either of non-childbearing potential or of childbearing potential. Females of childbearing potential must have negative pregnancy tests prior to randomization. Female subjects of childbearing potential must agree to use medically acceptable methods of contraception.
- Subjects must be able to read, write, and understand the language of the symptom diary.
Who cannot join
- Current or a history of esophageal motility disorders.
- Current or a history of Barrett's esophagus.
- Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).
- Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.
- Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.
- Inflammatory bowel disease.
Show all 9Show fewer
- Unstable diabetes mellitus.
- History of esophageal, gastric and duodenal surgery except simple suturing of an ulcer.
- Subjects who require daily use of nonsteroidal anti-inflammatory drugs (NSAIDs), oral steroids (>= 20 mg/day prednisone or equivalent), or aspirin (> 325 mg/day).
Trial locations and contacts
83 sites in 14 countries.
83 sites in 14 countries
India15 sites
Study site
Bangalore, Karnataka, 560054
Study site
Chennai, Tamil Nadu, 600096
Study site
Hyderabad, Andhra Pradesh, 500 082
Study site
Hyderabad, Andhra Pradesh, 500001
Study site
Hyderabad, Andhra Pradesh, 500004
Study site
Hyderabad, Andhra Pradesh, 500012
Study site
Hyderabad, Andhra Pradesh, 500063
Study site
Hyderabad, Andhra Pradesh, 500082
Study site
Kochi, Kerala, 682304
Study site
Ludhiana, Punjab, 141001
Study site
Madurai, Tamil Nadu, 625002
Study site
Mangalore, Karnataka, 575001
Study site
New Delhi, National Capital Territory of Delhi, 110029
Study site
Secunderabad, Andhra Pradesh, 500003
Study site
Visakhapatnam, Andhra Pradesh, 53002
Canada11 sites
Study site
Barrie, Ontario, L4M 7G1
Study site
Chatham, Ontario, N7L 1B9
Study site
Hamilton, Ontario, L8V 1C3
Study site
Richmond Hill, Ontario, L4B 3P8
Study site
Sarnia, Ontario, N7T 4X3
Study site
Saskatoon, Saskatchewan, S7K 1N4
Study site
Sherbrooke, Quebec, J1G 2E8
Study site
Toronto, Ontario, M3J 1N2
Study site
Toronto, Ontario, M3N 2V7
Study site
Toronto, Ontario, M4P 1P2
Study site
Toronto, Ontario, M9W 4L6
Hungary11 sites
Study site
Balatonfüred, Hungary, 8230
Study site
Budapest, Hungary, 1088
Study site
Budapest, Hungary, 1201
Study site
Debrecen, Hungary, 4032
Study site
Eger, Hungary, 3300
Study site
Győr, Hungary, 9024
Study site
Gyula, Hungary, 5700
Study site
Kaposvár, Hungary, 7400
Study site
Pécs, Hungary, 7624
Study site
Siófok, Hungary, 8601
Study site
Szekszárd, Hungary, 7100
Argentina8 sites
Study site
Buenos Aires, BUE, B1832BQS
Study site
Buenos Aires, BUE, C1117ABK
Study site
Ciudad Autonoma de Bs. As., CBA, 1431
Study site
Ciudad Autonoma de Bs. As., CBA, C1120AAT
Study site
Ciudad Autonoma de Bs. As., CBA, C1181ACH
Study site
La Plata, Argentina, 1900
Study site
Rosario, SFE, 2000
Study site
San Miguel de Tucumán, TUC, 4000
Germany8 sites
Study site
Dresden, Saxony, 1307
Study site
Freising, Bavaria, 85356
Study site
Herne, North Rhine-Westphalia, 44623
Study site
Ludwigshafen am Rhein, Rhineland-Palatinate, 67067
Study site
Mainz, Rhineland-Palatinate, 55131
Study site
Münster, North Rhine-Westphalia, 48167
Study site
Potsdam, BR, 14482
Study site
Wolmirstedt, Saxony-Anhalt, 39326
Australia7 sites
Study site
Adelaide, South Australia, 5001
Study site
Ballarat, Victoria, 3353
Study site
Caboolture, Queensland, 4510
Study site
Fitzroy, Victoria, 3065
Study site
Launceston, Tasmania, 7250
Study site
Penrith, New South Wales, 2751
Study site
Woodville, South Australia, 5011
Bulgaria5 sites
Study site
Haskovo, Bulgaria, 6300
Study site
Plovdiv, Bulgaria, 4000
Study site
Rousse, Bulgaria, 7002
Study site
Sofia, Bulgaria, 1527
Study site
Sofia, Bulgaria, 1606
Chile3 sites
Study site
Providencia, Chile
Study site
Santiago, Chile
Study site
Temuco, Chile
Croatia3 sites
Study site
Osijek, Croatia, 31 000
Study site
Split, Croatia, 21 000
Study site
Zagreb, Croatia, 10 000
France3 sites
Study site
Lyon, Lyonnais, 69437
Study site
Marseille, Provence, 13015
Study site
Saint-Quentin, France, 2100
Latvia3 sites
Study site
Balvi, Latvia, LV-4501
Study site
Daugavpils, Latvia, LV-5417
Study site
Riga, Latvia, LV-1006
Lithuania3 sites
Study site
Šiauliai, Lithuania, LT-76231
Study site
Vilnius, Lithuania, 3215
Study site
Vilnius, Lithuania, LT-08661
Estonia2 sites
Study site
Tallinn, Estonia, 10138
Study site
Tallinn, Estonia, 10617
About this study
Official title: A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).
Read the detailed description
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole Extended-Release (RAB ER) 50 mg or Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Being tested
- Rabeprazole sodium, Esomeprazole
- Keywords
- GERD, erosive GERD, erosive esophagitis
- Medical subject headings
- Gastroesophageal Reflux
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Rabeprazole sodiumDrug
Also called Aciphex
Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
EsomeprazoleDrug
Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
| Study group | Role | What they receive |
|---|---|---|
| 1 | Experimental | Not described Receives: Drug: Rabeprazole sodium |
| 2 | Active comparator | Not described Receives: Drug: Esomeprazole |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks
Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include:
Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.
Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.
Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.
Measured: Baseline and Week 8
Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include:
Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds.
Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference.
Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.
Measured: Baseline and Week 4
Secondary outcomes (1)
Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4
During the first 4 weeks of the Double-blind Phase, participants were to record heartburn in a daily diary. Participant daily symptoms for the assessment of heartburn was based on a commonly used 4-point Likert scale of none, mild, moderate and severe. A participant was considered achieving sustained resolution of heartburn if the participant had maintained at least 7 consecutive heartburn-free days.
Measured: Week 4
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Apr 2008 (estimated)
- Study startFeb 2008
- Primary completionSep 2009
- Study completionJan 2010
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Gastroesophageal Reflux Disease (GERD)Studies of the same condition, open and under way.
- More trials run by Eisai Inc.The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 1,069 participants (actual)
Sponsor and investigators
- Lead sponsor
- Eisai Inc.
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Yufang Lu, Study director, Eisai Inc.
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00658775
- Sponsor's protocol ID
- E3810-G000-302
- Other IDs
- 2007-006046-17
- Status last verified
- Nov 2015
- First submitted
- 9 Apr 2008
- Last updated
- 21 Dec 2015
- Results posted
- Yes, on ClinicalTrials.gov
Publications
Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. Aliment Pharmacol Ther. 2011 Jan;33(2):203-12. doi: 10.1111/j.1365-2036.2010.04516.x. Epub 2010 Nov 30.
PubMed 21114792
Study at a glance
From the registry record, last updated by the sponsor on 21 Dec 2015. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized, Double-Blind, Parallel Study of Rabeprazole Extended-Release 50 mg Versus Esomeprazole 40 mg for Healing and Symptomatic Relief of Moderate to Severe Erosive Gastroesophageal Reflux Disease (GERD)
- ClinicalTrials.gov ID
- NCT00658775
- Acronym / sponsor ID
- E3810-G000-302
- Conditions
- Gastroesophageal Reflux Disease (GERD)
- Keywords
- GERD, erosive GERD, erosive esophagitis
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,069 participants (actual)
- Lead sponsor
- Eisai Inc.Industry (pharma, biotech, devices)
- Study start
- Feb 2008
- Primary completion
- Sep 2009 (actual)
- Study completion
- Jan 2010 (actual)
- First posted
- 15 Apr 2008 (estimated)
- Results
- Posted 23 Jun 2015
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to investigate the efficacy (ie, healing and symptom relief) and safety of Rabeprazole Extended-Release (RAB ER) 50 mg versus Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).
Detailed description
This is a multicenter, randomized, double-blind, double-dummy, parallel-group study. Subjects who meet all the inclusion/exclusion criteria will be randomly assigned to 1 of 2 treatment groups, Rabeprazole Extended-Release (RAB ER) 50 mg or Esomeprazole (ESO) 40 mg for the treatment of moderate to severe erosive Gastroesophageal Reflux Disease (eGERD).
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| 1 | Experimental | Drug: Rabeprazole sodium |
| 2 | Active comparator | Drug: Esomeprazole |
Who may qualify
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- Male or female, ages 18 to 75 years.
- History of GERD symptoms for at least 3 months immediately before screening.
- Heartburn for at least 2 days a week for at least 1 month before screening.
- Esophageal erosions of LA Grades C or D based on EGD taken within 14 days prior to enrollment.
- Subjects who are H. pylori negative based on a screening test.
Key exclusion criteria (9 listed)
- Current or a history of esophageal motility disorders.
- Current or a history of Barrett's esophagus.
- Current esophageal strictures or esophagitis (known or suspected to be due to etiology other than GERD such as infection or medications).
- Current or a history of Zollinger-Ellison syndrome and other acid hypersecretory conditions, or current gastric or duodenal ulcer.
- Current or a history of cancer, with the exception of fully excised skin basal cell carcinoma.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Rabeprazole sodiumAlso: AciphexRabeprazole ER 50 mg capsule, once daily for 4-8 weeks. | Drug | 1 |
| EsomeprazoleEsomeprazole 40 mg capsule, once daily for 4-8 weeks. | Drug | 2 |
Primary outcome
Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks
Time frame: Baseline and Week 8
Healing at week 4 or 8 were based on improvement of eGERD of the Los Angeles (LA) classification of esophagitis Grade C or D from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.
Percentage of Participants With eGERD Who Achieved Endoscopically-confirmed Healing by 4 Weeks
Time frame: Baseline and Week 4
Healing at week 4 or 8 were based on improvement of eGERD of the LA classification of esophagitis Grade C or D from Baseline. Classifications include: Not Present: No breaks (erosions) in the esophageal mucosa (however, edema, erythema, or friability may be present) Grade A: One or more mucosal breaks not more than 5mm in maximum length. Grade B: One or more mucosal breaks more than 5mm in maximum length, but not continuous between the tops of 2 mucosal folds. Grade C: Mucosal breaks continuous between the tops of 2 or more mucosal folds, but involving less than 75% of the esophageal circumference. Grade D: Mucosal breaks involving at least 75% of the esophageal circumference.
1 secondary outcome
Percentage of Participants Who Achieved Diary-recorded Sustained Resolution of Heartburn by Week 4
Time frame: Week 4
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 21 Dec 2015.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 21114792Laine L, Katz PO, Johnson DA, Ibegbu I, Goldstein MJ, Chou C, Rossiter G, Lu Y. Randomised clinical trial: a novel rabeprazole extended release 50 mg formulation vs. esomeprazole 40 mg in healing of moderate-to-severe erosive oesophagitis - the results of two double-blind studies. Aliment Pharmacol Ther. 2011 Jan;33(2):203-12. doi: 10.1111/j.1365-2036.2010.04516.x. Epub 2010 Nov 30.
Related trials for Gastroesophageal Reflux Disease (GERD)
RecruitingObservational study
A Study to Evaluate the Efficacy and Safety of Long-term Administration of K-CAB Tab./K-CAB ODT(Tegoprazan) 25 mg as Maintenance Therapy Following the Treatment of GERD
Maintenance Therapy Following Treatment for Gastroesophageal Reflux Disease(GERD)
Active, not recruitingObservational study
RETHINK REFLUX Registry
Gastroesophageal Reflux
Recruiting
Transcatheter Mitral Valve Replacement in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO-EU Trial
Mitral Regurgitation
Not yet recruitingPhase 4
Effects of Tirzepatide on Esophagogastric Junction Mechanics, Reflux Burden, and Gastric Physiology in Adults With Obesity
Obese Adults
Recruiting
Mesh Vs Pledgets for Repair of Paraesophageal Hernia
Paraesophageal Hernia, GERD
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Yufang Lu study director
Eisai Inc.
83 sites in 14 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Rabeprazole sodium and Esomeprazole in people with Gastroesophageal Reflux Disease (GERD), run by Eisai Inc. at 83 sites in 14 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 21 Dec 2015. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 83 sites in India, Canada, Hungary, Argentina, Germany and 9 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 23 Jun 2015). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percentage of Participants With Erosive Gastroesophageal Reflux Disease (eGERD) Who Achieved Endoscopically-confirmed Healing by 8 Weeks (time frame: Baseline and Week 8). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00658775, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Dec 2015.